Skip to content
GMAB·Nasdaq·US

Genmab

Genmab is a biotechnology company focused on discovering, developing, and commercializing antibody-based therapeutics for cancer and other serious diseases. Its revenue is driven by royalties, collaboration revenue, reimbursement revenue, license fees, and net product sales from partnered and proprietary programs.

Recent Activity

Updated Oct 31, 2026
–Petosemtamab, an experimental drug Genmab gained in an $8 billion buyout, succeeded in a late-stage trial in a form of head and neck cancer.
–Genmab announced updated follow-up analyses from a Phase 2 study of petosemtamab in metastatic colorectal cancer, reporting encouraging objective response rates with promising depth and durability.
–Genmab and Incyte announced a clinical trial collaboration in metastatic colorectal cancer, with a Phase 1/2 study evaluating petosemtamab plus INCB161734 and standard-of-care chemotherapy.

Past updates are part of the Pro plan.

Thematic Position

GMAB

Relationship Groups

Suppliers5
Partners10
Licensing9
Competitors4

Relationship details are part of the Pro plan.

Ended Relationships

4 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

foreign investment screeningsanction
Danish FDI screening rules and trade/financial sanctions applicable to Genmab
SEC 20-FFeb 17, 2026

The full regulatory passage is part of the Pro plan.

4 more · Regulatory and geopolitical insights are part of the Pro plan.